Delcath Systems announces reimbursement for Chemostat in Chermany Delcath Systems announced that the Institut für das Entgeltsystem im Krankenhaus, the German federal reimbursement agency, has established a reimbursement pathway for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT Delivery System for melphalan hydrochloride. The Value 4 status given to the CHEMOSAT procedure, while not mandating reimbursement, allows participating cancer centers to negotiate reimbursement coverage for the CHEMOSAT procedure with all insurers serving their region. Under the NUB scheme, reimbursement pathways will potentially be available for treatment with CHEMOSAT regardless of primary cancer origin.
News For DCTH From The Last 14 Days
Check below for free stories on DCTH the last two weeks.